71 related articles for article (PubMed ID: 2487791)
1. [Role of serum markers and or various clinical parameters in the diagnosis of pancreatic carcinoma].
Meggiato T; Basso D; Piccoli A; Del Favero G; Fogar P; Panozzo MP; Scalon P; Fabris C; Angonese C; Faggian D
Ann Ital Med Int; 1989; 4(4):367-72. PubMed ID: 2487791
[TBL] [Abstract][Full Text] [Related]
2. Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach.
Fabris C; Del Favero G; Basso D; Piccoli A; Meggiato T; Angonese C; Plebani M; Leandro G; Burlina A; Naccarato R
Am J Gastroenterol; 1988 May; 83(5):549-53. PubMed ID: 3163228
[TBL] [Abstract][Full Text] [Related]
3. Limits of CEA and ferritin in the diagnosis of pancreatic cancer.
Plebani M; Fabris C; Basso D; Del Favero G; Angonese C; Leandro G; Di Mario F; Burlina A; Naccarato R
Int J Pancreatol; 1988; 3 Suppl 1():S113-7. PubMed ID: 3209864
[TBL] [Abstract][Full Text] [Related]
4. Role of local and systemic factors in increasing serum glycoprotein markers of pancreatic cancer.
Fabris C; Basso D; Piccoli A; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Faggian D; Vianello D; Plebani M
J Med; 1991; 22(3):145-56. PubMed ID: 1770322
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
6. [The role of CEA, CA 19-9 and TPA in the diagnosis of pancreatic cancer. Evaluation by discriminant analysis].
Basso D; Fabris C; Del Favero G; Panucci A; Piccoli A; Plebani M; Pedrazzoli S; Baccaglini U; Lise M; Burlina A
Minerva Med; 1986 Apr; 77(16):613-6. PubMed ID: 3458035
[TBL] [Abstract][Full Text] [Related]
7. Serum carcinoembryonic antigen in the differential diagnosis of pancreatic cancer: influence of tumour spread, liver impairment, and age.
Basso D; Fabris C; Del Favero G; Angonese C; Meggiato T; Infantino A; Plebani M; Piccoli A; Leandro G; Burlina A
Dis Markers; 1988; 6(3):203-7. PubMed ID: 3168400
[TBL] [Abstract][Full Text] [Related]
8. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
[TBL] [Abstract][Full Text] [Related]
9. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
[TBL] [Abstract][Full Text] [Related]
10. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
Hámori J; Arkosy P; Lenkey A; Sápy P
Acta Chir Hung; 1997; 36(1-4):125-7. PubMed ID: 9408313
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
12. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
13. Tissue polypeptide antigen, galactosyltransferase isoenzyme II and pancreatic oncofetal antigen serum determination: role in pancreatic cancer diagnosis.
Basso D; Fabris C; Panucci A; Del Favero G; Angonese C; Plebani M; Petrin P; Burlina A; Naccarato R
Int J Pancreatol; 1988; 3 Suppl 1():S95-100. PubMed ID: 3145303
[TBL] [Abstract][Full Text] [Related]
14. CA 19-9 in serum and pancreatic juice: its role in the differential diagnosis of resectable pancreatic cancer from chronic pancreatitis.
Malesci A; Evangelista A; Mariani A; Bersani M; Bonato C; Basilico M; Montorsi M; Beretta E
Int J Pancreatol; 1988; 3 Suppl 1():S119-23. PubMed ID: 3209865
[TBL] [Abstract][Full Text] [Related]
15. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R
Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354
[TBL] [Abstract][Full Text] [Related]
16. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
[TBL] [Abstract][Full Text] [Related]
18. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
Pasanen PA; Kauppinen R; Eskelinen M; Partanen K; Pikkarainen P; Alhava E
Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910
[TBL] [Abstract][Full Text] [Related]
19. Serum immunoreactive elastase: is it useful for the diagnosis of pancreatic cancer?
Gullo L; Pezzilli R; Ventrucci M; Lesi C; Zoni L; D'Ambrosi A; Alvisi V
Pancreas; 1989; 4(3):335-8. PubMed ID: 2734276
[TBL] [Abstract][Full Text] [Related]
20. [Differential diagnostic evaluation of chronic pancreatitis in relation to pancreatic cancer based on clinical, laboratory chemical and diagnostic parameters. Studies of 174 patients in 10 years].
Gronen G; Dombrowski H; Adler G; Lorenz-Meyer H
Z Gastroenterol; 1986 Aug; 24(8):416-25. PubMed ID: 3532595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
